Radiation Oncology Journal

  • 제31권3호
  • /
  • Pages.125-130
  • /
  • 2013
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Role of radiotherapy for pancreatobiliary neuroendocrine tumors

  • Lee, Jeongshim (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Choi, Jinhyun (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Choi, Chihwan (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine) ;
  • Seong, Jinsil (Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)
  • 투고 : 2013.05.27
  • 심사 : 2013.07.15
  • 발행 : 2013.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: We investigated the role of radiotherapy (RT) for pancreatobiliary neuroendocrine tumors (PB-NETs). Materials and Methods: We identified 9 patients with PB-NETs who received RT between January 2005 and March 2012. Of these 9 patients, 4 were diagnosed with NETs in the pancreas and 5 were diagnosed with NETs in the gallbladder. All patients received RT to the primary tumor or resection bed with a median total irradiation dose of 50.4 Gy, with or without chemotherapy. Results: The tumor response rate and tumor control rate in the RT field were 60% and 100 %, respectively. All 4 patients who underwent surgery had no evidence of disease in the RT field. Of the 5 patients who received RT to the primary gross tumor, 1 had complete response, 2 had partial response, and 2 had stable disease in the RT field. The median time to progression was 11 months. Of the 9 patients, four patients had no progression, and 5 patients had progression of disease (locoregional, 2; distant, 2; locoregional/distant, 1). Of the 4 patients without progression, 3 were treated with RT in adjuvant or neoadjuvant setting, and one received RT to primary tumor. One patient experienced radiation-induced duodenitis at 3 months after concurrent chemoradiation without treatment-related mortality. Conclusion: RT can yield local control for advanced PB-NETs. RT should be considered an essential part of multimodality treatment in management of advanced PB-NETs.

키워드

참고문헌

  1. Buchanan KD, Johnston CF, O'Hare MM, et al. Neuroendocrine tumors: a European view. Am J Med 1986;81:14-22. https://doi.org/10.1016/0002-9343(86)90581-4
  2. Lam KY, Lo CY. Pancreatic endocrine tumour: a 22-year clinicopathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 1997;23:36-42. https://doi.org/10.1016/S0748-7983(97)80140-0
  3. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794-803. https://doi.org/10.1093/annonc/mdq022
  4. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001;92:2204-10. https://doi.org/10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R
  5. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1-18. https://doi.org/10.1016/j.ecl.2010.12.005
  6. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19: 1727-33. https://doi.org/10.1093/annonc/mdn351
  7. Cho MY, Kim JM, Sohn JH, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat 2012;44:157-65. https://doi.org/10.4143/crt.2012.44.3.157
  8. Kulke MH, Benson AB 3rd, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw 2012;10:724-64. https://doi.org/10.6004/jnccn.2012.0075
  9. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23. https://doi.org/10.1056/NEJM199202203260804
  10. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  11. Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007; 85:216-20. https://doi.org/10.1159/000102969
  12. Torrisi JR, Treat J, Zeman R, Dritschilo A. Radiotherapy in the management of pancreatic islet cell tumors. Cancer 1987;60: 1226-31. https://doi.org/10.1002/1097-0142(19870915)60:6<1226::AID-CNCR2820600611>3.0.CO;2-7
  13. Rich TA. Radiation therapy for pancreatic cancer: eleven year experience at the JCRT. Int J Radiat Oncol Biol Phys 1985;11: 759-63. https://doi.org/10.1016/0360-3016(85)90308-6
  14. Saif MW, Ng J, Chang B, Russo S. Is there a role of radiotherapy in the management of pancreatic neuroendocrine tumors (PNET)? JOP 2012;13:174-6.
  15. Zagar TM, White RR, Willett CG, et al. Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:1126-31. https://doi.org/10.1016/j.ijrobp.2011.09.041
  16. Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-85. https://doi.org/10.1067/msy.2001.118367
  17. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62. https://doi.org/10.1200/JCO.2005.08.066
  18. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-23. https://doi.org/10.1056/NEJMoa1009290
  19. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-13. https://doi.org/10.1056/NEJMoa1003825
  20. Kulke MH, Bergsland EK, Ryan DP, et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-61. https://doi.org/10.1200/JCO.2006.05.6762

피인용 문헌

  1. A case of pancreatic neuroendocrine tumors vol.5, pp.1, 2013, https://doi.org/10.1007/s13691-015-0230-x
  2. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality? vol.15, pp.1, 2016, https://doi.org/10.1007/bf03401399
  3. Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors vol.47, pp.9, 2013, https://doi.org/10.1093/jjco/hyx081